| REVIEW ARTICLE |
|
| Year : 2020 | Volume
: 7
| Issue : 1 | Page : 3-6 |
|
|
Tryptase: A novel prognostic biomarker in chronic myeloid leukemia
Anisha Mathew1, Manisha Naithani1, Uttam Kumar Nath2
1 Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
2 Department of Medical Oncology Hematology, All India Institute of Medical Sciences, Rishikesh, Uttarakhand, India
Correspondence Address:
Dr. Manisha Naithani
Department of Biochemistry, All India Institute of Medical Sciences, Rishikesh, Uttarakhand
India
 Source of Support: None, Conflict of Interest: None
DOI: 10.4103/ami.ami_41_20
|
|
|
Chronic myeloid leukemia (CML) is a myeloproliferative neoplasm characterized by the presence of the Philadelphia chromosome. It is treated with tyrosine kinase inhibitor agents targeted against the breakpoint cluster region-Abelson murine leukemia 1 fusion transcript. Disease risk stratification at diagnosis of chronic-phase (CP) CML is done using Sokal, Hasford, and EUTOS scores which use basophilia as a major component. However, basophil counts can be both variable and inaccurate. The serum tryptase level is being studied as a novel biomarker which represents the total basophil compartment. Tryptase, deriving its name from trypsin-like activity commonly expressed by mast cells, and also by immature basophils of patients suffering from various myeloid and leukemic disorders, has a role in tumor proliferation. Patients with seemingly low-normal levels of basophils and raised tryptase levels progress further in disease despite treatment. There is a recent interest in the role of serum tryptase as a prognostic marker in CML-CP.
|
|
|
|
| [FULL TEXT] [PDF]* |
|
 |
|
